Invitrocue Ltd (ASX:IVQ) chief executive officer Steven Fang speaks to Proactive Investors about the oncology-focused company's development of cancer treatments by testing specific drugs on laboratory-controlled micro-tumours.
"We've been able to take some of these really innovative, disruptive technologies and apply it to the space of being able to create these micro-tumours," says Fang.
He continues, "That allows us to test the response of these cancer cells against those specific drugs.
"But it's always done individualised - this whole area of personalised oncology is now coming to market."
Meet Cardinal Resources Ltd, Legend Mining Ltd and Danakali Ltd at our event, Melbourne , 16 July 2019. Register here »